TickerKhojHospitals & Diagnostics · Hospital/Nursing Management · NSE: KIMS · data 2026-11-02
Krishna Institute of Medical Sciences Limited
In plain words
Price: 17.0% below its 52-week high of ₹858.
Delivery: 55.1% of traded shares were kept for delivery over the last 10 sessions, against 58.2% over the last 60.
Latest results: a net profit of ₹42 cr for the quarter ended Jun 2026 (-47.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹4,213 cr |
| Net profit (last 12 months) | ₹204 cr |
| Sales growth, 3 years (yearly) | 21.1% |
| Profit growth, 3 years (yearly) | -10.5% |
At a glance
Promoters 32.7% (-1.5 pts in a year), pledged 11.7%, institutions 48.2%.
P/E 140.8, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.0%, ROCE 9.5%, operating margin 11.9%: how much profit it earns on the money it uses.
Debt/equity 1.89, Profit growth -10.5% and sales growth 21.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- High borrowing: debt/equity 1.89.
- Profit fell 10.5% a year over 3 years.
- Promoters have pledged 11.7% of their shares.
- Promoters cut their holding by 1.5 points in a year.
- Expensive on earnings (P/E 140.8).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
KIMS Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹1,179.5 crore, up 35.3% YoY and up 9.8% QoQ.
Net profit was ₹41.5 crore, down 47.2% YoY and down 2.4% QoQ.
Operating margin was 18.9% (22.1% a year ago).
EPS was ₹1.04, down 46.9% YoY and down 1.9% QoQ.
KIMS के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹1,179.5 करोड़; पिछले साल की तुलना में 35.3% की बढ़त, पिछली तिमाही की तुलना में 9.8% की बढ़त।
शुद्ध मुनाफ़ा: ₹41.5 करोड़; पिछले साल की तुलना में 47.2% की गिरावट, पिछली तिमाही की तुलना में 2.4% की गिरावट।
ऑपरेटिंग मार्जिन: 18.9% (एक साल पहले 22.1%)।
EPS: ₹1.04; पिछले साल की तुलना में 46.9% की गिरावट, पिछली तिमाही की तुलना में 1.9% की गिरावट।
KIMSના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹1,179.5 કરોડ; ગયા વર્ષની સરખામણીએ 35.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 9.8% વધારો.
ચોખ્ખો નફો: ₹41.5 કરોડ; ગયા વર્ષની સરખામણીએ 47.2% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 2.4% ઘટાડો.
ઓપરેટિંગ માર્જિન: 18.9% (એક વર્ષ પહેલાં 22.1%).
EPS: ₹1.04; ગયા વર્ષની સરખામણીએ 46.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 1.9% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 0/30: Delivery 57.3% over the last 20 sessions vs 64.1% in the 40 before (0.89x); shares delivered per day 0.68x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 13 schemes hold it, about ₹2,151 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "Single spike", sustained score 18/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 29 Sept 26Insider SAST disclosure: Catalyst Trusteeship Limited acting… acquired 28,08,979 shares -2.6% next session
- 3 Aug 26Results Q1 FY27 results: profit −47.2% YoY -1.1% next session
- 15 May 26Results Q4 FY26 results: profit −58.3% YoY -7.3% next session
- 6 Feb 26Results Q3 FY26 results: profit −42.3% YoY +6.6% next session
- 7 Nov 25Results Q2 FY26 results: profit −37.5% YoY -2.7% next session
- 6 Aug 25Results Q1 FY26 results: profit −9.2% YoY +0.3% next session
- 13 May 25Results Q4 FY25 results: profit +55.5% YoY -1.8% next session
- 6 Feb 25Results Q3 FY25 results: profit +28.8% YoY -1.1% next session
- 9 Nov 24Results Q2 FY25 results: profit +16.5% YoY -1.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹1,180 cr | ₹42 cr | -47.2% | 18.9% | 1.04 |
| Mar 2026 | ₹1,075 cr | ₹43 cr | -58.3% | 19.2% | 1.06 |
| Dec 2025 | ₹998 cr | ₹53 cr | -42.3% | 19.9% | 1.33 |
| Sept 2025 | ₹961 cr | ₹67 cr | -37.5% | 21.2% | 1.67 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 32.66% | 32.50% | 34.11% | 34.11% |
| Foreign institutions (FII) | 15.01% | 14.74% | 14.57% | 14.33% |
| Domestic institutions (DII) | 33.22% | 34.43% | 32.50% | 32.71% |
| Mutual funds | 28.21% | 28.52% | 27.41% | 27.50% |
| Retail investors | 3.93% | 3.89% | 4.09% | 4.09% |
| Number of shareholders | 95,609 | 94,730 | 93,333 | 1,01,599 |
Common questions
What was Krishna Institute of Medical Sciences Limited's latest quarterly profit?
Krishna Institute of Medical Sciences Limited reported a net profit of ₹42 cr for the quarter ended Jun 2026 (-47.2% on the same quarter a year earlier), on revenue of ₹1,180 cr.
How much do promoters hold in Krishna Institute of Medical Sciences Limited?
Promoters held 32.66% of Krishna Institute of Medical Sciences Limited at the end of Sept 2026, with 11.71% of promoter shares pledged.
Is Krishna Institute of Medical Sciences Limited debt-free?
Its latest reported debt-to-equity ratio is 1.89, meaning borrowings are larger than shareholders' equity.
What is Krishna Institute of Medical Sciences Limited's P/E ratio?
About 140.8, based on the last 12 months' earnings and a price of ₹712.1 (data 2026-11-02).
What is the 52-week high and low of Krishna Institute of Medical Sciences Limited?
The 52-week high is ₹858 and the 52-week low is ₹575.8.
Mutual funds holding Krishna Institute of Medical Sciences Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 13 schemes holding about ₹2,151 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Smallcap Fund | SBI Mutual Fund | 2.00% | ₹821 cr |
| SBI MultiCap Fund | SBI Mutual Fund | 2.07% | ₹486 cr |
| NIPPON INDIA SMALL CAP FUND | Nippon India Mutual Fund | 0.56% | ₹453 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 3.39% | ₹119 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.69% | ₹99 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.69% | ₹98 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.89% | ₹31 cr |
| Nippon India Innovation Fund | Nippon India Mutual Fund | 0.91% | ₹27 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.89% | ₹16 cr |
| ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF | Aditya Birla Sun Life Mutual Fund | 1.76% | ₹1 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.89% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.48% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.89% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences Limited | ₹712.1 | ₹29,480 cr | 140.8 | — | 11% | 9.5% | 1.89 | -2.2% |
| Aster DM Quality Care Limited | ₹685.5 | ₹59,570 cr | 111.2 | — | 9.7% | 10.3% | 0.49 | -1.8% |
| Fortis Healthcare Ltd. | ₹767.5 | ₹58,117 cr | 55.3 | — | 11.1% | 12.3% | 0.35 | -26.5% |
| Narayana Hrudayalaya Ltd. | ₹1,799.5 | ₹35,144 cr | 42.6 | 7.3 | 19.8% | 14.5% | 1.29 | -0.5% |
| Global Health Limited | ₹1,308.2 | ₹34,122 cr | 63.3 | — | 15.1% | 13.2% | 0.3 | -4.2% |
| Rainbow Childrens Medicare Limited | ₹1,225.8 | ₹12,366 cr | 43.6 | — | 17.9% | 16.5% | 0.54 | -12.1% |
Compare KIMS with ASTERDM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KIMS in TickerKhoj →